Generation Bio Co.
GBIODelisted Feb 9, 2026- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001733294
Generation Bio Co. was delisted on Feb 9, 2026; its insiders filed their last Form 4 on Feb 9, 2026; 48 institutions reported holding it in 13F filings for Q4 2025, worth $24.5M in total; no superinvestor held it.
13F holders, Q3 2022
Institutional positions in Generation Bio Co. as of Sep 30, 2022. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 115
- +20 vs. Q2 2022
- Shares held
- 57.7M
- +2.34M (+4.2%) vs. Q2 2022
- Total value
- $306.3M
- −$57.2M (−15.7%) vs. Q2 2022
- New holders
- 27
- 43 more added
- Sold out
- 7
- 25 more reduced
Compare with Q2 2022: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting GBIO on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 1 | $0 |
| Q1 2026 | 2 | $53.3K |
| Q4 2025 | 48 | $24.5M |
| Q3 2025 | 41 | $24.2M |
| Q2 2025 | 63 | $13.3M |
| Q1 2025 | 81 | $19.3M |
| Q4 2024 | 80 | $57.1M |
| Q3 2024 | 77 | $136.4M |
| Q2 2024 | 79 | $156.5M |
| Q1 2024 | 77 | $223.7M |
| Q4 2023 | 76 | $86.7M |
| Q3 2023 | 77 | $216.8M |
| Q2 2023 | 81 | $315.1M |
| Q1 2023 | 86 | $246.8M |
| Q4 2022 | 98 | $224.5M |
| Q3 2022 | 115 | $306.3M |
| Q2 2022 | 95 | $363.5M |
| Q1 2022 | 89 | $415.8M |
| Q4 2021 | 89 | $390.3M |
| Q3 2021 | 82 | $1.20B |
| Q2 2021 | 98 | $1.25B |
| Q1 2021 | 88 | $1.27B |
Institutions, Q3 2022
Shares, value and share of portfolio for each institution holding Generation Bio Co.; share changes are against Q2 2022.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Goldman Sachs Group Inc | 815,576 | $4.33M | 0.00% | +601,954+281.8% | Added |
| Great Point Partners LLC | 825,077 | $4.38M | 1.05% | +825,077 | New |
| Geode Capital Management, LLC | 854,929 | $4.54M | 0.00% | +34,429+4.2% | Added |
| State Street Corp | 918,491 | $4.88M | 0.00% | +3,563+0.4% | Added |
| Yiheng Capital Management, L.P. | 997,857 | $5.30M | 0.50% | −1,599,774−61.6% | Reduced |
| Vanguard Group Inc | 2,218,522 | $11.8M | 0.00% | +8,213+0.4% | Added |
| Farallon Capital Management, L.L.C. | 2,500,000 | $13.3M | 0.08% | −397,300−13.7% | Reduced |
| Artal Group S.A. | 2,814,191 | $14.9M | 0.78% | 00.0% | Unchanged |
| PFM Health Sciences, LP | 3,013,712 | $16.0M | 0.61% | +240,399+8.7% | Added |
| T. Rowe Price Investment Management, Inc. | 3,482,617 | $18.5M | 0.01% | +3,482,617 | New |
| BlackRock Inc. | 3,616,045 | $19.2M | 0.00% | +114,082+3.3% | Added |
| Bellevue Group AG | 3,627,280 | $19.3M | 0.28% | 00.0% | Unchanged |
| Price T Rowe Associates Inc | 7,395,573 | $39.3M | 0.01% | −1,536,040−17.2% | Reduced |
| Atlas Venture Life Science Advisors, LLC | 8,278,876 | $44.0M | 4.85% | 00.0% | Unchanged |
| FMR LLC | 8,851,683 | $47.0M | 0.00% | +288,742+3.4% | Added |
| Lindbrook Capital, LLC | 0 | $0 | 0.00% | −283−100.0% | Sold out |
| Qube Research & Technologies Ltd | 0 | $0 | 0.00% | −76,914−100.0% | Sold out |
| Jane Street Group, LLC | 0 | $0 | 0.00% | −47,628−100.0% | Sold out |
| Ergoteles LLC | 0 | $0 | 0.00% | −44,549−100.0% | Sold out |
| DekaBank Deutsche Girozentrale | 0 | $0 | 0.00% | −19,400−100.0% | Sold out |
| Delphia (USA) Inc. | 0 | $0 | 0.00% | −16,850−100.0% | Sold out |
| Corton Capital Inc. | 0 | $0 | 0.00% | −15,493−100.0% | Sold out |